ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.740
-0.160 (-5.52%)
At close: Jul 15, 2025, 4:00 PM
2.750
+0.010 (0.36%)
After-hours: Jul 15, 2025, 7:53 PM EDT
ImmunityBio Stock Forecast
Stock Price Forecast
The 5 analysts that cover ImmunityBio stock have a consensus rating of "Strong Buy" and an average price target of $11.4, which forecasts a 316.06% increase in the stock price over the next year. The lowest target is $5 and the highest is $30.
Price Target: $11.4 (+316.06%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +994.89% | Jul 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +191.97% | Jun 4, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +994.89% | Jun 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +994.89% | May 28, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $4.25 → $5 | Hold → Buy | Upgrades | $4.25 → $5 | +82.48% | May 20, 2025 |
Financial Forecast
Revenue This Year
98.49M
from 14.75M
Increased by 567.98%
Revenue Next Year
256.63M
from 98.49M
Increased by 160.56%
EPS This Year
-0.48
from -0.62
EPS Next Year
-0.32
from -0.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 130.2M | 353.1M | 1.3B | ||
| Avg | 98.5M | 256.6M | 897.1M | ||
| Low | 81.9M | 174.1M | 549.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 783.0% | 258.5% | 390.6% | ||
| Avg | 568.0% | 160.6% | 249.5% | ||
| Low | 455.1% | 76.7% | 114.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.45 | -0.26 | 0.45 | ||
| Avg | -0.48 | -0.32 | 0.18 | ||
| Low | -0.54 | -0.46 | -0.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.